The year 2023 brought reports of highly effective glucagon-like peptide 1 (GLP1) mono-agonists or combinations with amylin receptor agonists. Results for monomolecular co-agonists that added glucagon receptor and/or glucose-dependent insulinotropic polypeptide (GIP) receptor agonism to GLP1 receptor activation were also published in 2023. Interestingly, antagonistic GIP receptor antibodies conjugated with a GLP1 agonist were also shown to be effective.